Omthera Pharmaceuticals, Inc. Files for a $75 Million IPO

Published: Mar 11, 2013

Omthera Pharmaceuticals has joined the wave of companies wanting to come public. Omthera is a clinical stage biotech and will trade under the ticker OMTH on Nasdaq after its initial public offering. The underwriting group consists of BofA/Merrill Lynch, Barclays, Leerink Swann, Stifel and Piper Jaffray. The company is an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for abnormalities in blood lipids and the treatment of cardiovascular disease. Epanova is currently its sole product candidate and is a late-stage, novel, omega-3 free fatty acid composition that meaningfully reduces triglycerides, improves other key lipid parameters and is expected to increase patient convenience with 2-gram once-a-day dosing with or without meals.

Back to news